Cancer treatment-induced bone loss in breast and prostate cancer.
about
Aromatase inhibitor-induced bone loss increases the progression of estrogen receptor-negative breast cancer in bone and exacerbates muscle weakness in vivoGeriatric considerations in the treatment of advanced prostate cancerBisphosphonates for osteoporosis treatment are associated with reduced breast cancer risk.Bone health issues in breast cancer survivors: a Medicare Current Beneficiary Survey (MCBS) study.Bone health in the prostate cancer patient receiving androgen deprivation therapy: a review of present and future management options.Cost-effectiveness of fracture prevention in men who receive androgen deprivation therapy for localized prostate cancer.Adverse effects of androgen deprivation therapy: defining the problem and promoting health among men with prostate cancer.Bone health in nonmetastatic prostate cancer: what's the big deal?Drug resistance in metastatic castration-resistant prostate cancer.Management options of breast cancer related osteoporosis.Treatment of osteopenia.Effects of a structured weight-bearing exercise program on bone metabolism among breast cancer survivors: a feasibility trialBiochemical markers of bone turnover and clinical outcomes in men with prostate cancerDisentangling the body weight-bone mineral density association among breast cancer survivors: an examination of the independent roles of lean mass and fat mass.Breast cancer and osteoporosis - management of cancer treatment-induced bone loss in postmenopausal women with breast cancer.Low rates of bone mineral density measurement in Medicare beneficiaries with prostate cancer initiating androgen deprivation therapyOptimizing clinical benefits of bisphosphonates in cancer patients with bone metastases.Construction of a database for the evaluation and the clinical management of patients with breast cancer treated with antiestrogens and/or aromatase inhibitors.Cancer Treatment-Induced Bone Loss in women with breast cancerLong-term health outcomes in a British cohort of breast, colorectal and prostate cancer survivors: a database study.Influence of weight training on skeletal health of breast cancer survivors with or at risk for breast cancer-related lymphedemaEffect of transforming growth factor beta (TGF-β) receptor I kinase inhibitor on prostate cancer bone growth.Exercise effects on hip bone mineral density in older, post-menopausal breast cancer survivors are age dependent.Androgen deprivation therapy toxicity and management for men receiving radiation therapyLong-term Toxicity of Cancer Treatment in Older PatientsPreventive care in older cancer survivorsImpact of denosumab on bone mass in cancer patients.Ligand-independent requirements of steroid receptors EcR and USP for cell survivalAromatase inhibitor-associated bone loss and its management with bisphosphonates in patients with breast cancerImpact + resistance training improves bone health and body composition in prematurely menopausal breast cancer survivors: a randomized controlled trial.Prostate cancer survivorship: prevention and treatment of the adverse effects of androgen deprivation therapy.Progress in osteoporosis and fracture prevention: focus on postmenopausal women.Osteonecrosis of the jaw and bisphosphonate use in breast cancer patients.Src kinase inhibitors: an emerging therapeutic treatment option for prostate cancer.Emerging drugs for the management of cancer treatment induced bone loss.Challenges in clinical patient management.Novel targeted agents on the horizon for castration-resistant prostate cancer.Drug development for metastatic castration-resistant prostate cancer: current status and future perspectives.Aging and osteoporosis in breast and prostate cancer.Bisphosphonate therapy in patients under androgen deprivation therapy for prostate cancer: a systematic review and meta-analysis.
P2860
Q30275126-9AF46704-0B5E-4426-83BA-1EB0B5EA7CE7Q33598327-54E12C46-A06C-4169-88E3-40C9CDA4A84AQ33708123-D75403C2-47AC-43E3-9970-3F64FE98B48CQ33725256-31BE4EB7-6AAB-459E-B071-DD3A62CE17F6Q33754036-7B98A609-384D-416E-BC6F-0FF52F5D7A34Q33789201-255E3C2E-2B6D-4D12-A712-D1E541D9F3C0Q33977523-67F94F2A-9B83-4C20-8A30-71882FBD1C8CQ34111621-27C152C2-B1FA-46BD-9085-E9FD80AD040EQ34139362-85FC26DC-C35C-477F-A472-2005B209E571Q34230292-B8F0BC50-B2C1-4B4E-8A43-03BB2586CCBCQ34630644-A0DF125C-823B-43C0-851C-01EA7258ABC9Q34765951-FE6415BC-0272-40D9-A2CA-B7848B2E2AEBQ35022212-D322F940-2896-4F75-91DE-74BC658E99EDQ35026624-D97FA057-5C86-49E7-A0AB-AF69B519CB52Q35066907-CD82C295-D1EF-436C-88D9-2F8F652BEA02Q35206815-3ACAC18C-9E8A-4E16-8E74-E0E1C831D1C6Q35583788-CC3584E1-FB85-4A2B-8CAB-7F19226F1874Q35593300-519DA7E3-E27C-4EA2-9FB3-75369768C575Q35632616-B4DE16FD-C11E-4A1E-BD4C-0701AC716131Q35654258-7FF615F0-9B84-43D5-85A9-B9E46E84888EQ35664164-581B2143-ADF4-4990-B717-FF63800F990CQ35754279-49CCDA71-C341-428D-8D7B-A000E8042807Q36497102-DB2AF6DF-74F0-4188-A7A7-7A53C1AE678BQ36530136-1504DFE5-CA9C-47E8-AB16-AE2A54F81A82Q36821673-E5DC4FF2-2D8C-4CE7-8948-115169EF81EEQ36904360-0B55FB7F-6843-4418-BB07-970960029599Q37000157-342AEC48-F604-43BE-9160-527F0C424506Q37354002-FA50CFA4-FF75-4556-BD05-F783A937FCBBQ37356084-638BBA73-13BE-4D9D-9C91-A77D263C89F8Q37376419-B4936EE1-72D2-4DC5-B6FF-60837F496934Q37390104-285F6408-04E4-403F-8AE7-0A61B1735326Q37453973-392B191A-7F0C-4AA9-B60F-1F2446FEBD3DQ37577926-AF23D728-6091-4038-AC26-EB703B3247C7Q37724378-0CE89EB2-6B53-4E7E-B74E-43FF3B54D888Q37727235-4A1945DB-B805-446F-A588-9EA9B063965CQ37775020-919DB215-0AA1-48A2-810C-AAC47C2C7BB0Q37818294-1451BA1D-00CB-48D0-B313-24CC4D02606CQ37861201-55B6756E-ECEF-4FF2-876E-A0F29B9D2597Q37872146-97266D97-F01F-40F7-85B7-CD9FE3ECC586Q37926896-83BB5DB7-9C7A-4EEB-818A-054C09FB25C0
P2860
Cancer treatment-induced bone loss in breast and prostate cancer.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 27 October 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Cancer treatment-induced bone loss in breast and prostate cancer.
@en
Cancer treatment-induced bone loss in breast and prostate cancer.
@nl
type
label
Cancer treatment-induced bone loss in breast and prostate cancer.
@en
Cancer treatment-induced bone loss in breast and prostate cancer.
@nl
prefLabel
Cancer treatment-induced bone loss in breast and prostate cancer.
@en
Cancer treatment-induced bone loss in breast and prostate cancer.
@nl
P2093
P356
P1476
Cancer treatment-induced bone loss in breast and prostate cancer.
@en
P2093
Jacques P Brown
Jonathan D Adachi
Karen A Gelmon
Leah A Canning
Robert G Josse
P304
P356
10.1200/JCO.2008.18.4184
P407
P577
2008-10-27T00:00:00Z